Edition:
India

SSY Group Ltd (2005.HK)

2005.HK on Hong Kong Stock

6.14HKD
24 May 2019
Change (% chg)

HK$0.02 (+0.33%)
Prev Close
HK$6.12
Open
HK$6.10
Day's High
HK$6.20
Day's Low
HK$6.03
Volume
4,778,000
Avg. Vol
5,394,622
52-wk High
HK$9.46
52-wk Low
HK$5.17

Latest Key Developments (Source: Significant Developments)

SSY Group Says Consistency Of Quality For Fluconazole Tablets Approved
Friday, 17 May 2019 

May 17 (Reuters) - SSY Group Ltd <2005.HK>::CONSISTENCY OF QUALITY AND EFFICACY EVALUATION FOR GENERIC DRUGS FOR FLUCONAZOLE TABLETS MADE BY UNIT APPROVED.NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED PASSING OF QUALITY AND EFFICACY FOR FLUCONAZOLE TABLETS.  Full Article

SSY Group Posts Qtrly Profit Attributable Of HK$261 Mln
Wednesday, 17 Apr 2019 

April 17 (Reuters) - SSY Group Ltd <2005.HK>::QTRLY TURNOVER RMB925 MILLION, UP 4.3%.QTRLY UNAUDITED PROFIT ATTRIBUTABLE HK$261 MILLION, UP 7.8%.  Full Article

SSY Group National Says Production And Registration For Moxifloxacin Hydrochloride And Sodium Chloride Injection Approved
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - SSY Group Ltd <2005.HK>::NATIONAL DRUG ADMINISTRATION OF CHINA APPROVES PRODUCTION AND REGISTRATION FOR MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION.APPROVAL FOR MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION IN NON- PVC SOFT BAG PACKAGING.  Full Article

SSY Group ‍Obtains China FDA Approvals For Drug Production For Hemofiltration Replacement Fluid
Thursday, 22 Mar 2018 

March 22 (Reuters) - SSY Group Ltd <2005.HK>::‍OBTAINED APPROVALS FOR DRUG PRODUCTION AND REGISTRATION FOR HEMOFILTRATION REPLACEMENT FLUID FROM CHINA FDA.  Full Article

Ssy Group Unit ‍Entered Agreement With Zhengzhou University For Research Of New Liver Fibrosis​ Drug
Monday, 5 Mar 2018 

March 5 (Reuters) - Ssy Group Ltd <2005.HK>::UNIT ‍ENTERED AGREEMENT WITH ZHENGZHOU UNIVERSITY IN RELATION TO RESEARCH AND DEVELOPMENT OF NEW DRUG USED FOR LIVER FIBROSIS​.‍ AGGREGATE INVESTMENT IN RESEARCH AND DEVELOPMENT OF DRUG FOR TREATMENT OF LIVER FIBROSIS​ IS RMB 50 MILLION.  Full Article

SSY Group Updates On Development Of Hemofiltration Basic Solution
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - SSY Group Ltd <2005.HK>::GETS ‍APPROVAL FOR DRUG PRODUCTION AND REGISTRATION FOR HEMOFILTRATION BASIC SOLUTION (4000ML) FROM CHINA FOOD AND DRUG ADMINISTRATION​.  Full Article

Ssy Group Sees FY ‍Profit Attributable Up In Range Of 30 Pct To 40 Pct
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Ssy Group Ltd <2005.HK>::‍PROFIT ATTRIBUTABLE FOR YEAR ENDED 31 DECEMBER 2017 IS EXPECTED TO INCREASE SIGNIFICANTLY RANGING FROM 30% TO 40%​.EXPECTED RESULT DUE TO ‍ INCREASES IN SALES VOLUME AND AVERAGE SELLING PRICE OF INTRAVENOUS INFUSION SOLUTIONS​.  Full Article

SSY Group Updates on Product Development
Monday, 11 Dec 2017 

Dec 11 (Reuters) - SSY Group Ltd <2005.HK>::SSY GROUP-OBTAINED APPROVAL FOR DRUG PRODUCTION & REGISTRATION FOR SODIUM ACETATE RINGER'S INJECTION (500ML) FROM CHINA FOOD & DRUG ADMINISTRATION​.  Full Article

SSY Group says turnover of group for 9 months ended Sept. 30, 2017, HK$2,105 mln, up 24.2 pct
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - SSY Group Ltd <2005.HK>::‍Gross profit margin of group for nine months ended Sept. 30, 2017 was 55.1​ percent, up 4.4 percent.‍Turnover of group for nine months ended 30 september 2017 is HK$2,105 million, up by 24.2 percent​.  Full Article

SSY Group obtains production approvals from FDA of Hebei province
Wednesday, 30 Aug 2017 

Aug 30 (Reuters) - Ssy Group Ltd <2005.HK>:Obtained production approvals for seven bulk pharmaceuticals as approved from food and drug administration of Hebei province.Production approvals were transferred from a PRC pharmaceutical company at a consideration of RMB35 million.  Full Article